It established two cohorts: 244,063 patients in the GLP-1 RA treatment group (Victoza, Saxenda, Ozempic, Wegovy) and 11,439,560 patients in the non-GLP-1 RA group
We expect that food, beverage and lifestyle-oriented companies should be among the consumer sectors likely to feel a gradual impact
The Phase 2 retatrutide trial (PMID 37366315) reported -24.2% body weight change at the 12 mg weekly dose across 48 weeks
Thats a meaningful run of consistent use long enough to see the full arc of results unfold, from the initial brightness uptick at two to four weeks through to measurable dark spot improvement at six to eight weeks
All efficacy and safety data is based on 7-day (once-weekly) intervals
Both types of treatments are reimbursed in some Canadian jurisdictions for adults with type 2 diabetes (semaglutide) or in patients with obesity and 1 weight-related comorbid condition (liraglutide, orlistat)